Celladon’s Mydicar Fails In Phase IIb, But Don’t Count Out Gene Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Shares of uniQure, Spark Therapeutics and bluebird bio all opened lower April 27 after Celladon announced its heart failure gene therapy Mydicar failed to show a benefit versus placebo in a mid-stage trial.
You may also be interested in...
Gene/Cell Therapies: Still Just A ‘Science Project’?
While an increasing number of South Korean biotech firms are looking to advance into overseas gene and cell therapy markets as part of the government's plan to develop these areas as a new growth engine, a U.S. regulatory expert has cautioned it is risky for bioventures to focus only on the gene and cell sectors while they still face major regulatory and commercialization hurdles.
VC Enthusiasm For Gene Therapy Is Going Viral
Audentes is the latest gene therapy start-up to land a large Series A round, taking $30 million to explore treatments for two rare muscle diseases. It’s another sign that VCs believe the risks around gene therapy are continuing to abate – and that pharmas aren’t far behind them.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.